ALTH Allos Therapeutics, Inc. (MM)

Allos to Present at Needham and Company's Third Annual Biotechnology Conference WESTMINSTER, Colo., June 10 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. (NASDAQ:ALTH) announced today that the company will participate in Needham and Company's Third Annual Biotechnology Conference which is being held June 16-17 in New York City. Michael E. Hart, President and Chief Executive Officer of Allos will give a 35-minute presentation on June 16th at 1:30 p.m. ET. The presentation will be webcast live and may be accessed by visiting the Allos website at http://www.allos.com/. A replay of the webcast will also be available on the company's website until Wednesday, June 30, 2004. About Allos Therapeutics, Inc. Allos Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing innovative drugs for improving cancer treatments. The company's lead clinical candidate, RSR13 (efaproxiral), is a synthetic small molecule that has the potential to sensitize hypoxic (oxygen deprived) tumor tissues and enhance the efficacy of standard radiation therapy. In addition, Allos is developing PDX, a novel small molecule cytotoxic injectable antifolate (DHFR inhibitor) being developed for non-small cell lung cancer, mesothelioma and non-Hodgkin's lymphoma. For more information, please visit the company's web site at: http://www.allos.com/. DATASOURCE: Allos Therapeutics, Inc. CONTACT: Fern Lazar of Lazar Partners, +1-212-867-1762 for Allos Therapeutics, Inc. Web site: http://www.allos.com/

Copyright